Emergent BioSolutions Inc.·4

Feb 10, 7:07 PM ET

Williams Paul Anthony 4

4 · Emergent BioSolutions Inc. · Filed Feb 10, 2026

Research Summary

AI-generated summary of this filing

Updated

Emergent BioSolutions SVP Paul Williams Sells 8,655 Shares

What Happened
Williams Paul Anthony, SVP, Products Business at Emergent BioSolutions (EBS), had a disposition to the issuer on Feb 6, 2026: 8,655 shares were disposed at $10.92 per share for $94,513. In the same settlement, 1,022 shares were withheld to cover tax liabilities at the same $10.92 price for $11,160. These transactions relate to the settlement of performance-based equity (see footnotes); the transactions are sales/withholdings rather than open-market purchases.

Key Details

  • Transaction date: February 6, 2026. Price: $10.92 per share.
  • Disposition (D): 8,655 shares — $94,513. Tax withholding (F): 1,022 shares — $11,160.
  • Shares owned after the reported transactions: not disclosed in the filing.
  • Footnote F1: These were performance stock units (PSUs) under the company’s Stock Incentive Plan. The Compensation Committee certified 2023–2025 PSUs at a 25% payout, resulting in an actual award of 2,884 shares on Feb 6, 2026 (less than earlier estimates).
  • Footnote F2 / code F: 1,022 shares were withheld to pay taxes associated with vesting/settlement of restricted awards.
  • Filing: Report filed Feb 10, 2026; based on the Feb 6 transaction date this appears to be timely.

Context
The primary event was settlement of performance-based equity (PSUs) certified at a 25% payout of target. The disposition to the issuer and the shares withheld for taxes are administrative steps commonly used to net-settle awards and cover tax obligations — not an open-market sale. For retail investors, purchases typically carry more interpretive weight; this filing documents routine award settlement and tax withholding rather than a spontaneous insider buy.

Insider Transaction Report

Form 4
Period: 2026-02-06
Williams Paul Anthony
SVP, Products Business
Transactions
  • Disposition to Issuer

    Common Stock

    [F1]
    2026-02-06$10.92/sh8,655$94,51377,216 total
  • Tax Payment

    Common Stock

    [F2]
    2026-02-06$10.92/sh1,022$11,16076,194 total
Footnotes (2)
  • [F1]Consists of performance stock units granted under the Emergent BioSolutions Inc. Stock Incentive Plan. Each PSU represents a right to receive one share of common stock. The PSUs vest upon achievement with respect to both cumulative revenues and adjusted EBITDA as a percentage of total GAAP revenue calculated on a cumulative basis over the three-year period beginning January 1, 2023 and ending December 31, 2025. On February 06, 2026, the final certification date, the Compensation Committee certified the achievement of the 2023-2025 PSUs at a payout factor of 25% of target resulting in the actual award of 2,884 shares of common stock, which is less than the 11,539 shares previously reported on March 02, 2023 and June 09, 2023.
  • [F2]Represents shares of common stock withheld to pay taxes associated with vesting and settlement of restricted stock units
Signature
/s/ Richard S. Lindahl, Attorney-in-fact|2026-02-10

Documents

1 file
  • 4
    wk-form4_1770768441.xmlPrimary

    FORM 4